Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Bayer's Hyrnuo Enters HER2-Mutated Lung Cancer Market, Challenging Boehringer's Hernexeos

Bayer's Hyrnuo Enters HER2-Mutated Lung Cancer Market, Challenging Boehringer's Hernexeos

The U.S. Food and Drug Administration (FDA) has granted accelerated approval to Bayer's Hyrnuo (sevabertinib) for the treatment of HER2-mutated non-small cell lung cancer (NSCLC), marking a significant development in the pharmaceutical industry's approach to this rare tumor type. This approval positions Hyrnuo as a direct competitor to Boehringer Ingelheim's Hernexeos, which received FDA approval just a few months earlier.

NoahAI News11/20/2025
GSK Initiates Collaborations with Flagship Pioneering Biotechs in $7B Deal

GSK Initiates Collaborations with Flagship Pioneering Biotechs in $7B Deal

GSK has taken a significant step forward in its partnership with Flagship Pioneering by selecting two biotechnology companies for its first collaborations under a $7 billion biobucks agreement. The British pharmaceutical giant has signed separate feasibility agreements with Profound Therapeutics and Quotient Therapeutics, both portfolio companies of Flagship Pioneering, focusing on discovering new targets and therapeutic approaches for respiratory and liver diseases.

NoahAI News11/20/2025
Independence Health System to Join WVU Health System in $800 Million Deal

Independence Health System to Join WVU Health System in $800 Million Deal

In a significant move that will reshape the healthcare landscape in western Pennsylvania, Independence Health System has announced plans to join the West Virginia University Health System. The deal, set to close in the fall of 2026, includes a substantial $800 million investment from WVU Health System to expand clinical services and modernize facilities across Independence's network.

NoahAI News11/20/2025
Moderna Invests $140M in New US Manufacturing Facility, Strengthening Domestic mRNA Production

Moderna Invests $140M in New US Manufacturing Facility, Strengthening Domestic mRNA Production

Moderna, a leading mRNA-based therapeutics and vaccines company, has announced plans to invest $140 million in a new manufacturing facility at its Norwood, Massachusetts campus. This strategic move aims to bring end-to-end mRNA production to the United States, reinforcing the company's commitment to domestic manufacturing and bolstering its supply chain resilience.

NoahAI News11/20/2025
Merck KGaA and Valo Health Forge $3B Partnership for Parkinson's Drug Discovery

Merck KGaA and Valo Health Forge $3B Partnership for Parkinson's Drug Discovery

In a significant development for the pharmaceutical industry, Merck KGaA has entered into a strategic partnership with Flagship Pioneering's Valo Health, aiming to revolutionize drug discovery for Parkinson's disease. The collaboration, announced on November 20, 2025, leverages Valo's advanced AI-enabled platforms and extensive human biology data to identify novel therapeutic targets.

NoahAI News11/20/2025
Antheia Partners with TAPI to Advance Biomanufacturing of Drug Ingredients

Antheia Partners with TAPI to Advance Biomanufacturing of Drug Ingredients

Antheia, a biomanufacturing company specializing in synthetic biology, has announced a strategic partnership with TAPI, Teva Pharmaceutical Industries' active pharmaceutical ingredient (API) and contract manufacturing arm. This collaboration aims to accelerate the commercialization of Antheia's pipeline of biosynthetic drug ingredients and key starting materials (KSMs).

NoahAI News11/20/2025
Novartis Unveils Ambitious $771 Million Expansion Plan for North Carolina Manufacturing Hub

Novartis Unveils Ambitious $771 Million Expansion Plan for North Carolina Manufacturing Hub

Novartis, the Swiss pharmaceutical giant, has announced a significant expansion of its manufacturing presence in North Carolina, with plans to invest up to $771 million and create 700 new jobs. The company aims to establish a "flagship manufacturing hub" in the state, bolstering its U.S. production capabilities and strengthening the domestic pharmaceutical supply chain.

NoahAI News11/20/2025
Lundbeck's $2.4B Bid for Avadel Sparks Pharmaceutical Industry Bidding War

Lundbeck's $2.4B Bid for Avadel Sparks Pharmaceutical Industry Bidding War

In a dramatic turn of events, the pharmaceutical industry is witnessing yet another high-stakes bidding war as Lundbeck has made an unsolicited $2.4 billion takeover offer for Avadel Pharmaceuticals, challenging Alkermes' existing acquisition agreement. This development comes on the heels of the recent Pfizer-Novo Nordisk battle over obesity biotech Metsera, signaling an increasingly competitive landscape in pharmaceutical mergers and acquisitions.

NoahAI News11/19/2025
Pharmaceutical Industry Shake-Up: Mergers, FDA Drama, and Pricing Shifts

Pharmaceutical Industry Shake-Up: Mergers, FDA Drama, and Pricing Shifts

In a week of significant developments, the pharmaceutical industry has seen major acquisitions, regulatory challenges, and unprecedented pricing strategies. These events are reshaping the landscape of drug development and healthcare policy.The pharmaceutical sector is experiencing a surge in merger and acquisition activity. Merck has made a bold move with a $9.2 billion offer for Cidara Therapeutics, signaling confidence in the smaller biotech's pipeline. This deal follows closely on the heels of Johnson & Johnson's $3 billion acquisition of Halda Therapeutics, further consolidating the industry.

NoahAI News11/19/2025
Alkermes Sweetens Deal to Acquire Avadel, Outbidding Lundbeck in Pharmaceutical Industry Shake-up

Alkermes Sweetens Deal to Acquire Avadel, Outbidding Lundbeck in Pharmaceutical Industry Shake-up

In a dramatic turn of events in the pharmaceutical industry, Alkermes has increased its offer to acquire Avadel Pharmaceuticals, outmaneuvering a surprise bid from Lundbeck. The intensifying acquisition battle highlights the growing importance of sleep disorder treatments in the pharmaceutical landscape.

NoahAI News11/19/2025
FDA Clears Dexcom's Smart Basal Software for Type 2 Diabetes Insulin Management

FDA Clears Dexcom's Smart Basal Software for Type 2 Diabetes Insulin Management

Dexcom, a leader in continuous glucose monitoring (CGM) technology, has received FDA clearance for its innovative Smart Basal software, designed to optimize basal insulin dosing for adults with Type 2 diabetes. This breakthrough marks a significant advancement in diabetes management, offering a more personalized and data-driven approach to insulin therapy.

NoahAI News11/19/2025
Celltrion Expands Beyond Biosimilars with $350M TriOar Antibody Platform Deal

Celltrion Expands Beyond Biosimilars with $350M TriOar Antibody Platform Deal

Celltrion, the Korean pharmaceutical giant known primarily for its biosimilars, is making significant strides to diversify its portfolio. In a move that signals a shift in strategy, the company has secured an option to utilize TriOar's innovative antibody platform in a deal that could be worth over $350 million.

NoahAI News11/19/2025
«1...313233...67»